CXI Healthcare Technology Group Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CXI Healthcare Technology Group.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth	10.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

Sep 30

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Aug 05

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

May 30

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CXI Healthcare Technology Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A900120 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	69,420	29,349	43,666	43,666	N/A
3/31/2024	67,194	21,013	42,610	42,610	N/A
12/31/2023	68,673	17,446	41,272	41,272	N/A
9/30/2023	69,715	12,117	35,049	35,049	N/A
6/30/2023	71,617	7,528	31,597	31,597	N/A
3/31/2023	79,065	1,294	33,115	33,121	N/A
12/31/2022	87,718	3,198	34,513	34,519	N/A
9/30/2022	98,052	9,532	37,885	37,891	N/A
6/30/2022	101,376	5,981	35,979	35,984	N/A
3/31/2022	103,312	6,182	31,884	34,802	N/A
12/31/2021	105,354	4,302	-78,688	33,577	N/A
9/30/2021	108,284	2,762	-131,371	24,526	N/A
6/30/2021	104,593	5,098	-196,165	8,723	N/A
3/31/2021	81,035	-55,823	-279,044	-11,374	N/A
12/31/2020	64,812	-70,201	-182,182	-23,860	N/A
9/30/2020	63,264	-83,142	-152,506	-37,816	N/A
6/30/2020	63,406	-98,437	-110,022	-44,322	N/A
3/31/2020	82,358	-61,945	-41,425	-41,418	N/A
12/31/2019	106,374	-64,559	-51,724	-51,707	N/A
9/30/2019	117,046	-67,216	-50,748	-50,706	N/A
6/30/2019	129,309	-70,621	-58,101	-58,060	N/A
3/31/2019	147,921	-64,977	-64,012	-63,977	N/A
12/31/2018	149,568	-66,308	-60,023	-59,997	N/A
9/30/2018	148,347	-72,578	-64,361	-64,361	N/A
6/30/2018	145,264	-73,933	-57,435	-57,435	N/A
3/31/2018	120,456	-70,977	N/A	-34,471	N/A
12/31/2017	120,228	-49,884	N/A	-13,879	N/A
9/30/2017	125,336	-24,445	N/A	14,958	N/A
6/30/2017	146,319	786	N/A	54,284	N/A
3/31/2017	190,109	18,964	N/A	48,143	N/A
12/31/2016	228,969	29,945	N/A	65,841	N/A
9/30/2016	269,185	42,624	N/A	75,067	N/A
6/30/2016	297,600	52,396	N/A	59,172	N/A
3/31/2016	311,164	60,931	N/A	88,396	N/A
12/31/2015	318,262	66,823	N/A	86,723	N/A
9/30/2015	321,330	71,473	N/A	89,229	N/A
6/30/2015	317,895	73,452	N/A	95,513	N/A
3/31/2015	312,412	69,309	N/A	77,966	N/A
12/31/2014	303,794	68,530	N/A	74,266	N/A
9/30/2014	291,664	65,401	N/A	75,546	N/A
6/30/2014	286,376	63,604	N/A	77,930	N/A
3/31/2014	285,469	66,365	N/A	87,930	N/A
12/31/2013	279,352	62,672	N/A	83,793	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A900120's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A900120's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A900120's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A900120's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A900120's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A900120's Return on Equity is forecast to be high in 3 years time

CXI Healthcare Technology Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New major risk - Shareholder dilution

CXI Healthcare Technology Group Limited announced that it has received KRW 999.999999 million in funding from Beauty Skin Corp.

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

Investor sentiment improves as stock rises 28%

New major risk - Shareholder dilution

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

CKH Food & Health Limited announced that it has received KRW 7.432995165 billion in funding

New minor risk - Share price stability

Investor sentiment improves as stock rises 35%

Investor sentiment deteriorates as stock falls 16%

New major risk - Shareholder dilution

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

No independent directors

Investor sentiment improved over the past week

CKH Food & Health Limited announced that it has received KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited

CKH Food & Health Limited announced that it expects to receive KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited, and other investors

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99981 million.

Third quarter 2021 earnings released: ₩9.00 loss per share (vs ₩139 loss in 3Q 2020)

CKH Food & Health Limited announced that it has received KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it expects to receive KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it has received KRW 679.08 million in funding

CKH Food & Health Limited announced that it expects to receive KRW 679.08 million in funding

Second quarter 2021 earnings released: ₩17.00 loss per share (vs ₩133 loss in 2Q 2020)

New 90-day low: ₩405

First quarter 2021 earnings released: EPS ₩10.00

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩354

New 90-day high: ₩295

New 90-day high: ₩274

New 90-day low - ₩212

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies